Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.

BACKGROUND--In the day to day care of obstructive airways diseases (asthma and chronic obstructive pulmonary disease) important decisions such as disease classification and choice of therapy are based on assessment of the bronchodilator response. However, surprisingly little is known of the long term course of the bronchodilator response in patients with obstructive airways disease. METHODS--Data from a multicentre trial were used in which 274 patients aged 18-60 years with airways obstruction were selected with PC20 < 8 mg/ml and FEV1 < 95% CI of predicted. FEV1 was measured before and 20 minutes after 1000 micrograms terbutaline and 40 minutes after an additional 80 micrograms ipratropium bromide. Data were analysed from 185 patients who were followed up for 21 months (five measurements). Four different expressions of bronchodilator response (BDR) were examined for change under long term therapy, long term variability, and prognostic value in predicting response to inhaled corticosteroids. RESULTS--There was a significant reduction in BDR of 117 ml after three months of treatment with a beta 2 agonist plus a corticosteroid (BA + CS), but not after bronchodilators only. Significant reductions with BA + CS were also found in BDR as a percentage of initial FEV1, and in BDR as a percentage of predicted FEV1. Bronchodilator tests were quite variable (SD 186 ml or 11% of initial value) and less than half of the patients could consistently be classified as "irreversible" with recommended cutoff levels. The bronchodilator response at the start of the study proved to be a poor predictor of improvement in FEV1 under BA + CS treatment (correct prediction 60%). CONCLUSIONS--Bronchodilator responses decrease substantially with inhaled corticosteroid therapy, and within subject variability is considerable both in asthma and chronic obstructive pulmonary disease. Dichotomous decisions on whether patients are "irreversible" according to any single bronchodilator measurement should therefore be made with great caution. The bronchodilator response cannot be used accurately as a predictor of response to inhaled corticosteroids in obstructive airways disease.

[1]  Y. B. Cho,et al.  Interpretation of Bronchodilator Response inPatients with Obstructive Airway Disease , 1995 .

[2]  D. Postma,et al.  A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. , 1992, The New England journal of medicine.

[3]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[4]  C. van Weel,et al.  A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1. , 1992, The European respiratory journal.

[5]  D. Postma,et al.  Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. , 1992, Thorax.

[6]  D. Postma,et al.  Long-term multicentre trial in chronic nonspecific lung disease: methodology and baseline assessment in adult patients. Dutch CNSLD Study Group. , 1992, The European respiratory journal.

[7]  S. Chinn.  Statistics in respiratory medicine. 2. Repeatability and method comparison. , 1991, Thorax.

[8]  P. Sherwood Burge,et al.  Measures of reversibility in response to bronchodilators in chronic airflow obstruction: relation to airway calibre. , 1991, Thorax.

[9]  P. Burge,et al.  Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. , 1990, Thorax.

[10]  B. Spears.  Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma?: Higgins RM, Stradling JR, Lane DJ Chest 94:718–722 Aug 1988 , 1989 .

[11]  A. Renzetti,et al.  Clinical interpretation of airway response to a bronchodilator: epidemiologic considerations. , 1989, The American review of respiratory disease.

[12]  J. Stradling,et al.  Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma? , 1988, Chest.

[13]  P. Quanjer.  Predicted values: how should we use them? , 1988, Thorax.

[14]  V. Thomas,et al.  Cumulative dose-response curves for assessing combined effects of salbutamol and ipratropium bromide in chronic asthma. , 1988, The European respiratory journal.

[15]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[16]  P. Paré,et al.  Mechanics of airway narrowing. , 2015 .

[17]  Anthonisen Nr,et al.  Bronchodilator response in chronic obstructive pulmonary disease. , 1986 .

[18]  N. Anthonisen,et al.  Bronchodilator response in chronic obstructive pulmonary disease. , 1986, The American review of respiratory disease.

[19]  A C Degraff,et al.  The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables. , 1985, The American review of respiratory disease.

[20]  H. G. Morris.  Mechanisms of action and therapeutic role of corticosteroids in asthma. , 1985, The Journal of allergy and clinical immunology.

[21]  M. Leslie,et al.  Short term variability in FEV1: relation to pretest activity, level of FEV1, and smoking habits. , 1984, Thorax.

[22]  A. Miller,et al.  Standardized lung function testing. , 1984, Bulletin europeen de physiopathologie respiratoire.

[23]  R. Abboud,et al.  The short-term bronchodilator effects of fenoterol and ipratropium in asthma. , 1982, The Journal of allergy and clinical immunology.

[24]  N. Anthonisen,et al.  Steroid response in stable chronic obstructive pulmonary disease. , 1982, Annals of internal medicine.

[25]  S. Freedman,et al.  A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response. , 1978, Thorax.

[26]  F. Hargreave,et al.  Bronchial reactivity to inhaled histamine: a method and clinical survey , 1977, Clinical allergy.

[27]  K. Palmer,et al.  Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. , 1975, British medical journal.